Transgene Enrolls First Patients in Trial of TG 1042 in CBCL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

Transgene S. A. has announced that the first patients have been enrolled in a two-step phase II trial of its immunotherapy product candidate TG 1042 (Ad-IFNϒ) to treat relapsing cutaneous B-cell lymphoma (CBCL).

STRASBOURG, France—Transgene S. A. has announced that the first patients have been enrolled in a two-step phase II trial of its immunotherapy product candidate TG 1042 (Ad-IFNϒ) to treat relapsing cutaneous B-cell lymphoma (CBCL). TG 1042 is an adenoviral vector containing the human interferon gamma gene. In the first stage, 13 patients will be enrolled at centers in the United States, France, and Switzerland. If results are positive, recruitment will continue with an additional 28 patients in a second confirmatory stage. Patients will receive 4 months of intralesional injections of TG 1042 to induce an anti-tumor immune response. For more information about the trial: go to www.clinicaltrials.gov (search for NCT00394693).

Articles in this issue
Curcumin Evaluated for the Treatment of Pancreatic Cancer
Tykerb Approved for Metastatic HER2+ Breast Cancer
'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients
Drug for BPH May Also Reduce the Risk of Prostate Cancer
Phase III Trial of Prostvac-VF Is Launched
Electronic System Reminds Patients to Schedule Exams
Phase II Trial of Panzem for Renal Cell Carcinoma Initiated
Chemotherapy May Enrich Tumorigenic Cells in Breast Ca
Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway
Watchful Waiting Management for Prostate Ca a Hard Sell
Once-Weekly SC Idraparinux Equals Standard DVT Rx
Patients Using Unapproved Cancer Agent
CT Lung Screens: No Lives Saved
Transgene Enrolls First Patients in Trial of TG 1042 in CBCL
FDA Updates Warning Labels of ESAs in Cancer Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.